Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
CC transcript
Director departure
Inv. presentation
Orexigen Therapeutics, Inc. (OREXQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/12/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
03/15/2016 8-K Investor presentation
Docs: "Certificate of Designations, Preferences and Rights of Series Z Non-Convertible, Non-Voting Preferred Stock",
"Securities Purchase Agreement, by and among the Company and each purchaser party thereto",
"Investor Rights Agreement, by and among the Company, Baupost, and the other investors party thereto",
"Form of Indenture to be entered into between the Company and U.S. Bank National Association, as trustee and collateral agent",
"Form of Warrant",
"Form of Note",
"Form of Security Agreement",
"Orexigen announces strategic acquisition of all U.S. rights to Contrave ® , the market leading branded anti-obesity prescription medicine",
"Corporate Presentation"
09/20/2012 8-K Investor presentation
Docs: "Slide Presentation"
09/05/2012 8-K Investor presentation
Docs: "Slide Presentation"
01/10/2012 8-K Investor presentation
Docs: "Slide Presentation"
09/27/2011 8-K Investor presentation
Docs: "Slide Presentation"
12/17/2010 8-K Form 8-K - Current report
04/13/2010 8-K Investor presentation
Docs: "Slide Presentation"
01/11/2010 8-K Investor presentation
Docs: "Slide Presentation"
10/01/2009 8-K Investor presentation
Docs: "Conference Call Transcript"
09/30/2009 8-K Investor presentation
Docs: "Orexigen ® Therapeutics Phase 2b Trial for Empatic TM Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients New Data Highlights Strength of Company's Obesity Franchise with Two Late Stage Drug Candidates",
"Slide Presentation of Results"
07/20/2009 8-K Investor presentation
Docs: "-Contrave ® Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- -Contrave helps obese patients initiate and sustain meaningful weight loss, improves multiple",
"Slide Presentation of Top-line Results"
01/09/2009 8-K Investor presentation
Docs: "Orexigen Therapeutics Announces First of Four Phase 3 Trials of Contrave Meets Co- Primary and Key Secondary Endpoints",
"Conference Call Transcript",
"Slide Presentation of Top-line Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy